title: [Study of pathogenicity of Nipah virus and its vaccine development].
abstract: Nipah virus (NiV), a paramyxovirus, was first discovered in Malaysia in 1998 in an outbreak of infection in pigs and humans, and incurred a high fatality rate in humans. We established a system that enabled the rescue of replicating NiVs from a cloned DNA. Using the system, we analyzed the functions of accessory proteins in infected cells and the implications in in vivo pathogenicity. Further, we have developed a recombinant measles virus (rMV) vaccine expressing NiV envelope glycoproteins, which appeared to be an appropriate to NiV vaccine candidate for use in humans.
authors.affiliation: Laboratory Animal Research Center, Institute of Medical Science, The University of Tokyo.
authors.forename: Misako
authors.initials: M
authors.lastname: Yoneda
mesh_terms: D000818:Animals; D004279:DNA, Viral; D055808:Drug Discovery; D019204:GTP-Binding Proteins / Q000276:immunology; D005814:Genes, Viral / Q000235:genetics; D006023:Glycoproteins; D045464:Henipavirus Infections / Q000517:prevention & control / Q000821:virology*; D006801:Humans; D008458:Measles Vaccine / Q000235:genetics; D008459:Measles virus / Q000235:genetics; D045405:Nipah Virus / Q000235:genetics* / Q000472:pathogenicity* / Q000502:physiology; D010957:Plasmids / Q000235:genetics; D011995:Recombination, Genetic; D059386:Reverse Genetics; D014614:Vaccines, Synthetic / Q000235:genetics; D054334:Viral Regulatory and Accessory Proteins / Q000502:physiology; D014765:Viral Vaccines; D014779:Virus Replication
chemical_list: D004279:DNA, Viral; D006023:Glycoproteins; D008458:Measles Vaccine; D014614:Vaccines, Synthetic; D054334:Viral Regulatory and Accessory Proteins; D014765:Viral Vaccines; D019204:GTP-Binding Proteins